Breast cancer is the presence of malignant breast nodule, mass or abscess.
Most common symptom of breast cancer is a new lump or mass in the
breast. The lump or mass is usually painless, hard & irregular but
it can also be tender, soft, rounded or painful.
Other signs & symptoms include breast pain or nipple pain, nipple
discharge, nipple retraction and presence of breast skin changes (eg
peau d' orange, nipple excoriation, scaling, inflammation, skin
tethering, ulceration, abscess).
Trastuzumab emtansine improved overall survival (OS) compared with capecitabine plus lapatinib in patients previously treated for locally advanced or metastatic, unresectable, HER2-positive breast cancer, according to final results of the phase III EMILIA* trial.
The addition of pertuzumab to standard-of-care therapy may convey a positive, albeit modest, effect for women with HER2-positive breast cancer, according to findings from the APHINITY* trial presented at the annual meeting of the American Society of Clinical Oncology (ASCO 2017) held in Chicago, Illinois, US.
New drug applications approved by US FDA as of 1 - 15 May 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
One-year adjuvant treatment with trastuzumab improves disease-free survival (DFS) in women with HER2-positive early breast cancer who have completed primary treatment, according to the final analysis of the HERA* trial.
Extending the interval between doses of zoledronic acid does not increase skeletal events in individuals with bone metastases due to breast or prostate cancer, or multiple myeloma, according to a US study.
Palbociclib, in combination with letrozole, significantly improves progression-free survival (PFS) in Asian postmenopausal women with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) metastatic breast cancer compared with letrozole alone, according to a sub-analysis of Asian patients enrolled in the PALOMA-2* study presented at the recent European Society for Medical Oncology Asia 2016 Congress (ESMO Asia 2016) in Singapore.
A new scalp cooling device appears to reduce chemotherapy-related alopecia in women with early-stage breast cancer, according to results of the SCALP* trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US.
Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US.
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.